Chandigarh, January 6, 2026 – Nectar Lifesciences Limited has seen strong demand in its ongoing share buyback, with the offer subscribed 1.60 times as of 9:20 a.m. on January 6, 2026, the final day of the tender window.
The company is executing a fixed-price buyback of up to 3 crore equity shares at ₹27 per share, with the offer period running from December 31, 2025 to January 6, 2026.
Buyback Snapshot
| Particulars | Details |
|---|---|
| Company | Nectar Lifesciences Limited |
| Symbol | NECLIFE |
| Series | BB |
| Offer Type | Buyback |
| Issue Type | Fixed Price |
| Offer Price | ₹27 per equity share |
| Face Value | ₹1 |
| Issue Size | 3,00,00,000 equity shares |
| Offer Period | December 31, 2025 to January 6, 2026 |
Subscription Status
(As on January 6, 2026 | 9:20 a.m.)| Category | Shares Bid |
|---|---|
| Qualified Institutional Buyers (QIBs) | 5,42,951 |
| Non-Institutional Investors | 1,69,98,109 |
| Individual Investors | 3,04,90,139 |
| Total | 4,80,31,199 |
Category-wise Demand Trends
Individual investors continued to dominate the book, bidding for 3.05 crore shares, accounting for the largest share of demand as the buyback approaches closure.Corporate participation under the non-institutional category remained firm, with bids of nearly 1.70 crore shares, reinforcing oversubscription levels.
QIB participation stayed modest but steady at 5.43 lakh shares, broadly in line with earlier sessions.
Price-wise Order Book
| Offer Price (₹) | No. of Orders | Demat Quantity | Physical Quantity | Total Quantity |
|---|---|---|---|---|
| 27.00 | 8,410 | 4,80,31,199 | – | 4,80,31,199 |
About the Company
Nectar Lifesciences Limited is a listed entity that completed the divestment of its pharmaceutical operating businesses in 2025. The company is currently focused on capital optimisation and evaluating new strategic opportunities, with the ongoing buyback aimed at returning surplus funds to shareholders while streamlining its equity base.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.